DBV Technologies (NASDAQ:DBVT) Downgraded to “Sell” Rating by Wall Street Zen

DBV Technologies (NASDAQ:DBVT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Several other equities research analysts have also issued reports on DBVT. Guggenheim reaffirmed a “buy” rating and set a $51.00 target price on shares of DBV Technologies in a research report on Friday. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Citizens Jmp raised their price objective on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday. Cantor Fitzgerald set a $48.00 price objective on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, HC Wainwright set a $40.00 target price on shares of DBV Technologies in a research note on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.65.

DBV Technologies Stock Down 1.0%

DBV Technologies stock opened at $20.00 on Friday. DBV Technologies has a 52 week low of $5.30 and a 52 week high of $26.18. The company’s 50 day moving average price is $21.58 and its two-hundred day moving average price is $17.22. The stock has a market cap of $1.11 billion, a P/E ratio of -3.83 and a beta of -0.97.

DBV Technologies (NASDAQ:DBVT) last released its earnings results on Thursday, March 26th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.96). The business had revenue of $0.64 million during the quarter, compared to the consensus estimate of $1.06 million. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 310.56%. On average, equities analysts anticipate that DBV Technologies will post -7.05 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vivo Capital LLC bought a new stake in DBV Technologies in the 2nd quarter valued at about $9,659,000. MPM Bioimpact LLC bought a new position in DBV Technologies during the second quarter worth about $9,649,000. Adage Capital Partners GP L.L.C. bought a new position in DBV Technologies during the second quarter worth about $9,659,000. Octagon Capital Advisors LP purchased a new position in shares of DBV Technologies in the second quarter worth about $9,315,000. Finally, New York State Common Retirement Fund purchased a new position in shares of DBV Technologies in the third quarter worth about $34,000. Institutional investors own 71.74% of the company’s stock.

Key DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.